KRAS G12S clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    open to eligible people ages 18 years and up

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

    San Francisco, California and other locations

Our lead scientists for KRAS G12S research studies include .

Last updated: